Glaukos (NYSE:GKOS) announced today that it entered into a settlement with Ivantis to terminate a three-year-old patent infringement lawsuit. San Clemente, California-based Glaukos’ patent infringement lawsuit, initiated on April 14, 2018, in the U.S. District Court for the Central District of California, Southern Division, concerned Ivantis’ Hydrus Microstent for reducing eye pressure in glaucoma patients. Get the full […]
Glaukos
Glaukos submits supplemental PMA application for iStent Infinite
Glaukos (NYSE:GKOS) announced today that it submitted a supplemental premarket approval application to the FDA for its iStent Infinite system. San Clemente, California–based Glaukos designed the iStent Infinite trabecular micro-bypass system for use in a standalone procedure to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma uncontrolled by prior surgery or medical therapy. Get […]
Glaukos beats The Street in Q2, grows sales 147%
Glaukos (NYSE:GKOS) posted second-quarter results today that beat the overall consensus on Wall Street. The San Clemente, Calif.-based company reported losses of -$17.5 million, or -38¢ per share, on sales of $78.1 million for the three months ended June 30 for a sales growth of 147.46% compared with Q2 2020. Adjusted to exclude one-time items, earnings […]
The 18 most innovative medical devices of 2021
The Galien Foundation today announced the nominees for most innovative medical devices for its 15th annual Prix Galien USA Awards. The foundation nominates devices, biotechnology and pharmaceutical products for its annual Prix Galien awards to highlight products designed to improve the human condition. “The Awards Committee is excited to introduce the nominees for the 2021 […]
Glaukos wins Australian regulatory approval for MicroShunt
Glaukos (NYSE:GKOS) recently announced that it received regulatory approval from Australia’s Therapeutic Goods Administration for its Preserflo MicroShunt. The San Clemente, Calif.–based company designed the MicroShunt to reduce intraocular pressure in the eyes of patients who have primary open-angle glaucoma where IOP remains uncontrollable or where glaucoma progression needs surgery. Get the full story on our […]
Glaukos completes enrollment in Phase 3 trials for iDose TR drug-eluting implant
Glaukos (NYSE:GKOS) announced today that it completed enrollment for a Phase 3 clinical program for its iDose TR sustained-release travoprost implant. San Clemente, Calif.–based Glaukos’ iDose TR implant contains a novel formulation of travoprost, a prostaglandin analog used to reduce intraocular pressure (IOP) through a design that continuously releases therapeutic levels of the medication for […]
Glaukos beats The Street in Q1 results
Glaukos (NYSE:GKOS) posted first-quarter results that beat the overall consensus on Wall Street. The San Clemente, Calif.-based ophthalmic medical technology company yesterday reported losses of -$16.469 million, or -36¢ per share, on sales of $67.968 million for the three months ended March 31, for a sales growth of 22.83% compared with Q1 2020. Adjusted to […]
Glaukos inks licensing deal with Intratus for Eyelid drug delivery platform
Glaukos (NYSE:GKOS) announced today that it entered into a licensing agreement with Intratus over its Eyelid drug delivery platform. San Clemente, Calif.-based Glaukos was granted a global exclusive license to research, develop, manufacture and commercialize Intratus’ patented, non-invasive Eyelid drug delivery platform for treating presbyopia, according to a news release. Financial terms were not disclosed. Get the full […]
The 18 most innovative medical devices of 2020
The Galien Foundation recently announced nominees for most innovative medical devices for its 14th Annual Prix Galien USA Awards. The foundation bestows the Prix Galien Award annually to examples of outstanding biomedical and technology products that are designed to improve the human condition. “As we celebrate 50 years of the Prix Galien process, we are honored […]
Glaukos announces $200m offering
Glaukos (NYSE:GKOS) announced today that it intends to offer convertible senior notes worth $200 million in a private offering. San Clemente, Calif.-based Glaukos is offering the notes, due in 2027, only to qualified institutional buyers with a 13-day option for initial purchasers to purchase up to an additional $30 million in notes, according to a news […]
Glaukos down despite Street-beating Q4
Glaukos (NYSE:GKOS) shares plummeted today despite fourth-quarter results that beat the consensus forecast. GKOS shares dropped down -27.4% at $44.60 per share in early-morning trading today. The San Clemente, Calif.–based ophthalmic medical technology and pharmaceutical company posted profits of $36.6 million, or 84¢ per share, on sales of $65.8 million for the three months ended Dec. […]
